Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11925884 | 0.90 | KDR (1.00) | KDRFGFR3 | |
| SCHEMBL11907995 | 0.90 | FGFR3 (1.00) | KDRFGFR3 | |
| SCHEMBL13336654 | 0.85 | KDR (0.75) | KDRFGFR3 | |
| SCHEMBL3322152 | 0.85 | KDR (0.73) | KDRFGFR3 | |
| SCHEMBL3321690 | 0.85 | KDR (0.74) | KDRFGFR3 | |
| SCHEMBL11929648 | 0.84 | FGFR3 (1.00) | KDRFGFR3 | |
| SCHEMBL3318779 | 0.84 | KDR (0.72) | KDRFGFR3 | |
| SCHEMBL3321614 | 0.83 | KDR (0.78) | KDRFGFR3 | |
| Formic Acid SCHEMBL3323341 | 0.83 | KDR (0.71) | KDRFGFR3 | |
| SCHEMBL3321150 | 0.83 | KDR (0.80) | KDRFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | KDR 50/4885FGFR3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.